Altrius Capital Management Inc Has $7.18 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Altrius Capital Management Inc trimmed its position in shares of Sanofi (NASDAQ:SNY) by 0.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,209 shares of the company’s stock after selling 926 shares during the period. Sanofi comprises 2.1% of Altrius Capital Management Inc’s holdings, making the stock its 8th biggest holding. Altrius Capital Management Inc’s holdings in Sanofi were worth $7,180,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of Sanofi by 17.0% during the first quarter. FMR LLC now owns 23,282,201 shares of the company’s stock valued at $1,267,017,000 after purchasing an additional 3,387,606 shares during the period. Bank of America Corp DE increased its position in shares of Sanofi by 17.0% during the first quarter. Bank of America Corp DE now owns 10,626,939 shares of the company’s stock worth $578,318,000 after acquiring an additional 1,541,832 shares during the period. BlackRock Inc. raised its stake in shares of Sanofi by 2.5% during the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock valued at $546,804,000 after acquiring an additional 249,619 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Sanofi by 19.3% in the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock valued at $374,513,000 after purchasing an additional 1,251,199 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Sanofi by 20.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 7,556,281 shares of the company’s stock worth $407,284,000 after purchasing an additional 1,282,350 shares during the period. 10.06% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY stock traded down $0.21 during midday trading on Monday, hitting $46.81. 298,168 shares of the stock traded hands, compared to its average volume of 1,755,297. The stock’s fifty day simple moving average is $51.21 and its 200-day simple moving average is $52.26. The firm has a market cap of $118.41 billion, a P/E ratio of 14.74, a PEG ratio of 2.04 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 27th. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.02. The business had revenue of $13.02 billion during the quarter, compared to the consensus estimate of $13.61 billion. Sanofi had a return on equity of 27.55% and a net margin of 17.34%. On average, analysts expect that Sanofi will post 4.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. StockNews.com began coverage on Sanofi in a report on Thursday, October 5th. They issued a “buy” rating for the company. Berenberg Bank upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 5th. Finally, Stifel Nicolaus lowered Sanofi from a “buy” rating to a “hold” rating in a report on Monday, October 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.